Country |
|
Cannabis resin |
Cannabis leaves | ||||||
|---|---|---|---|---|---|---|---|---|---|
Sample size |
Min. |
Max. |
Ave. |
Sample size |
Min. |
Max. |
Ave. | ||
Belgium |
(1) |
|
4 |
7 |
5.5 |
|
4 |
6 |
5 |
Czech Republic |
(2) |
|
6.3 |
15.7 |
11 |
|
0.9 |
9.4 |
5.8 |
Denmark |
|
|
2.3 |
3.8 |
|
|
|
|
|
Germany |
|
|
|
|
6 |
|
|
|
7.3 |
Estonia |
|
|
9 |
16 |
12 |
|
7.7 |
15 |
11 |
Greece |
|
|
4 |
6 |
|
|
1.5 |
5 |
|
Spain |
|
|
|
|
1.4 |
|
|
|
1.1 |
France |
|
|
5 |
7 |
6 |
|
4 |
7 |
5 |
Italy |
|
|
7 |
8.6 |
|
|
5.4 |
6.6 |
|
Cyprus |
|
|
|
|
14.8 |
|
|
|
10.2 |
Latvia |
|
|
15 |
20 |
17.5 |
|
10 |
14 |
12 |
Lithuania |
|
|
6 |
15 |
10 |
|
3 |
15 |
9 |
Luxembourg |
|
|
|
|
8.3 |
|
|
|
8.1 |
Hungary |
|
4 |
4.8 |
8 |
4.8 |
5 |
3.2 |
10 |
4.8 |
Netherlands |
(3) |
53 |
|
10.5 |
6.5 |
17 |
|
8 |
4.9 |
Austria |
|
|
7 |
8 |
|
|
3 |
4 |
|
Poland |
|
|
4.5 |
11.4 |
8 |
|
3.4 |
5.7 |
4.5 |
Portugal |
|
|
|
|
2.5 |
|
|
|
4 |
Slovenia |
(4) |
|
8 |
9 |
8.5 |
|
2.5 |
4.4 |
3.5 |
Slovakia |
|
|
|
|
|
|
5 |
10.5 |
7.8 |
Finland |
|
|
|
|
10 |
|
|
|
|
Sweden |
|
41 |
7 |
11 |
9 |
30 |
3 |
16 |
8 |
United Kingdom |
(5) |
|
|
|
3.5 |
|
|
|
3.8 |
United Kingdom |
(6) |
216 |
2 |
8.1 |
4 |
128 |
2 |
8.1 |
5.4 |
Norway |
(7) |
|
17.9 |
25 |
21.5 |
|
|
|
|
Notes: Min. = minimum price recorded; Max. = maximum price recorded; Ave. = average price recorded. Data were not available in 2003 for the un-listed EU member states. Cannabis leaves refers to herbal cannabis. (1) Figures reported as averages are actually middle points between minimum and maximum prices. (2) Figures reported as averages are actually middle points between minimum and maximum prices. (3) Cannabis resin refers to imported cannabis resin; cannabis leaves refers to imported herbal cannabis. There is also data available for locally-produced cannabis (nederwiet): sample na, min. na, max. 10.32 and average 5.97. (4) Figures reported as averages are actually middle points between minimum and maximum prices. (5) The source is the National Crime Intelligence Service (NCIS). (6) The source is the Independent Drug Monitoring Unit (IDMU). (7) Figures reported as averages are actually middle points between minimum and maximum prices. Source: Reitox national focal points see [Table PPP-1 part (ii)] | |||||||||